



(51) International Patent Classification:

A61K 39/395 (2006.01) *G01N 33/53* (2006.01)*C07K 16/24* (2006.01) *A61P 19/02* (2006.01)

(21) International Application Number:

PCT/US2017/067917

(22) International Filing Date:

21 December 2017 (21.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/437,143 21 December 2016 (21.12.2016) US


(71) Applicant: **CEPHALON, INC.** [US/US]; 41 Moores Road, Frazer, Pennsylvania 19355 (US).(72) Inventors: **LAINE, David Jose Simon**; c/o Teva Pharmaceutical Industries, Ltd., 16 Basel Street, 4951033 Petach Tikva (IL). **POLLARD, Matthew**; c/o Teva Pharmaceutical Industries, Ltd., 16 Basel Street, 4951033 Petach Tikva (IL). **DOYLE, Anthony Gerard**; c/o Teva Pharmaceutical Industries, Ltd., 16 Basel Street, 4951033 Petach Tikva (IL). **POULTON, Lynn Dorothy**; c/o Teva Pharmaceuti-cal Industries, Ltd., 16 Basel Street, 4951033 Petach Tikva (IL). **CLARKE, Adam William**; c/o Teva Pharmaceutical Industries, Ltd., 16 Basel Street, 4951033 Petach Tikva (IL).(74) Agent: **SHEA, Jr, Timothy J.** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, N.W., Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ANTIBODIES THAT SPECIFICALLY BIND TO HUMAN IL-15 AND USES THEREOF

Figure 2A



(57) Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*